Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 2/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.45 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1195122 | 1.00 | PKM (0.56) | PKML3MBTL1BRAFPTGS2CA2 | |
| SCHEMBL3674001 | 0.97 | BRAF (0.55) | PKML3MBTL1BRAFPTGS2CA2 | |
| SCHEMBL3674003 | 0.97 | BRAF (0.55) | PKML3MBTL1BRAFPTGS2CA2 | |
| SCHEMBL3666484 | 0.89 | CA2 (0.52) | BRAFPTGS2CA2CA1CA4 | |
| SCHEMBL3666482 | 0.89 | CA2 (0.52) | BRAFPTGS2CA2CA1CA4 | |
| SCHEMBL4185178 | 0.87 | PKM (0.57) | PKML3MBTL1BRAFPTGS2KMT2A | |
| SCHEMBL4185174 | 0.87 | PKM (0.57) | PKML3MBTL1BRAFPTGS2KMT2A | |
| SCHEMBL4185180 | 0.87 | PKM (0.57) | PKML3MBTL1BRAFPTGS2KMT2A | |
| SCHEMBL3674686 | 0.82 | BRAF (0.56) | PKML3MBTL1BRAFPTGS2KMT2A | |
| SCHEMBL3674688 | 0.82 | BRAF (0.56) | PKML3MBTL1BRAFPTGS2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4780885-B2 | — | — | 2011-09-28 | — | — | JP | claimed |
| EP-1223923-B1 | UNSATURATED ARYL SULFONES FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | UNIV TEMPLE (US) | 2010-03-31 | — | — | EP | claimed |
| US-7595347-B2 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | Temple University—Of the Commonwealth System of Higher Education (US) | 2009-09-29 | — | — | US | claimed |
| EP-1223923-A4 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | UNIV TEMPLE (US) | 2007-09-05 | — | — | EP | claimed |
| US-20040214903-A1 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | COSENZA STEPHEN C (US) | 2004-10-28 | — | — | US | claimed |
| US-6767926-B1 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2004-07-27 | — | — | US | claimed |
| EP-1223923-A1 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2002-07-24 | — | — | EP | claimed |
| WO-2001026645-A1 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2001-04-19 | — | — | WO | claimed |
| US-9713597-B2 | Stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfone | ONCONOVA THERAPEUTICS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20150265549-A1 | STABLE AQUEOUS FORMULATION OF (E)-4-CARBOXYSTYRYL-4-CHLOROBENZYL SULFONE | ONCONOVA THERAPEUTICS, INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150238448-A1 | FORMULATION OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES | ONCONOVA THERAPEUTICS, INC (US) | 2015-08-27 | — | — | US | disclosed |
| US-9060967-B2 | Stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfone | ONCONOVA THERAPEUTICS, INC (US) | 2015-06-23 | — | — | US | disclosed |
| EP-2552199-B1 | IMPROVED STABLE AQUEOUS FORMULATION OF (E)-4-CARBOXYSTYRYL-4-CHLOROBENZYL SULFONE | ONCONOVA THERAPEUTICS INC (US) | 2015-06-03 | — | — | EP | disclosed |
| US-9044427-B2 | Compositions and methods for prevention and treatment of wounds | ONCONOVA THERAPEUTICS, INC (US) | 2015-06-02 | — | — | US | disclosed |
| US-6656973-B2 | Anticancer chemotherapy, and cytoprotective agents administered before, during or after chemotherapy to protect the normal cells of the patient | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-12-02 | — | — | US | disclosed |
| US-20030149109-A1 | (E)-4-carboxystyrl-4-chlorobenzyl sulfone and pharmaceutical compositions thereof | COSENZA STEPHEN C (US) | 2003-08-07 | — | — | US | disclosed |
| US-20030060505-A1 | Method for protecting cells and tissues from ionizing radiation toxicity with alpha, beta unsaturated aryl sulfones | ONCONOVA THERAPEUTICS, INC. | 2003-03-27 | — | — | US | disclosed |
| WO-2002069892-A2 | METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH α, β UNSATURATED ARYL SULFONES | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2002-09-12 | — | — | WO | disclosed |
| EP-1223923-A1 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001026645-A1 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060505-A1 | Method for protecting cells and tissues from ionizing radiation toxicity with alpha, beta unsaturated aryl sulfones | ARSA, SULT2A1, CYP2S1 | PKM 2881/4885L3MBTL1 1052/4885BRAF 2710/4885 |
| US-20040214903-A1 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | TOP1, TOP2A, PCNA | PKM 2968/4885L3MBTL1 1420/4885BRAF 3919/4885 |
| US-20150238448-A1 | FORMULATION OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES | ARSA, AHR, SULT2A1 | PKM 3291/4885L3MBTL1 2450/4885BRAF 2233/4885 |
| US-20150265549-A1 | STABLE AQUEOUS FORMULATION OF (E)-4-CARBOXYSTYRYL-4-CHLOROBENZYL SULFONE | TTPA, EBP, ADH1A | PKM 922/4885L3MBTL1 3210/4885BRAF 654/4885 |
| US-20030149109-A1 | (E)-4-carboxystyrl-4-chlorobenzyl sulfone and pharmaceutical compositions thereof | CCNE1, CCNE2, TOP2B | PKM 1977/4885L3MBTL1 899/4885BRAF 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.